Phase II study of modulation of sorafenib (SOR)-induced autophagy using hydroxychloroquine (HCQ) in advanced hepatocellular cancer (HCC): Planned interim efficacy and safety analysis.

Authors

Sukeshi Patel Arora

Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX

Sukeshi Patel Arora , Jennifer L. Moseley , Laura LaNiel Tenner , Luisa Arellano , Mary Salazar , Qianqian Liu , Joel Michalek , Devalingam Mahalingam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Evaluating the safety and efficacy of the addition of liver radiation (RT) to atezolizumab and bevacizumab (A/B) in advanced hepatocellular carcinoma (HCC): A retrospective cohort analysis.

First Author: Timothy J. Brown

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).

First Author: Arndt Vogel

insert_chart_outlined

Poster

2020 Gastrointestinal Cancers Symposium

bookmark_border

Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).

First Author: Masatoshi Kudo

insert_chart_outlined

Poster

2019 Gastrointestinal Cancers Symposium

bookmark_border

Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).

First Author: Bridget Keenan